Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGN-R08b in Type II Gaucher Disease
NCT06272149Phase 1Recruiting
- Sponsor
- Xinhua Hospital
- Start
- Mar 2023
- Primary completion
- Jan 2025
- Modality
- Gene Editing, Gene Silencing, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VGN-R08b in Gaucher disease type 2 (GD2), sponsored by Xinhua Hospital. Primary endpoint: Number of Adverse Events (AEs), Serious Adverse Events (SAEs) at 52 weeks. Started Mar 2023; status: recruiting.
02
Drugs
VGN-R08b
03
Conditions
Gaucher disease type 2 (GD2)
Beyond the preview
Go deeper on NCT06272149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06272149.